100 percent subcutaneous | | Reported weight data | 12.4 % (36 mg, 72 wk, ATTAIN-1) | 24.2 % (12 mg, 48 wk, Phase 2) | | Food restriction | None | Not applicable | | Status | FDA-approved (Foundayo, April 2026) | Research substance, not approved | The table illustrates that the higher weight values of retatrutide result from a broader receptor activation and the injection-driven complete entry of the active substance, while orforglipron has its strength in ease of administration and oral availability
During this transition, the breast milk safety question still applies
1,000 US adults ages 18+, including 200 who have ever been on a GLP-1 drug, were surveyed during January 20, 2025
Cysteine is the limiting amino acid for the bodys synthesis of glutathione so it does make sense that oral NAC can increase cellular levels
If youre ready to see whether prescription GLP-1 treatment may fit your needs, you can take the free assessment quiz to begin the review process
Rekha Kumar, an endocrinologist and chief medical officer of the weight management company Found